Hoping that positive results will be achieved, China has allowed for clinical trials of Gilead Science's remdesivir. 761 patients are to be involved in this clinical trial.
This decision was made following the promising preclinical results of chloroquine and remdesivir.
In-vitro results show that these two grugs actively inhibit the novel Corona Virus (2019-nCoV).
These compounds have been used in human patients before and have been reported to have a safety track record by a team of researchers and these two drugs were assessed along with five other drugs.
Though it is reported that remdesivir is sufficiently effective, investigations are still underway and therefore, more information will be coming through.
No comments:
Post a Comment
Due to the high number of spammy comments we have decided to initiate comment moderation so that we can maintain our quality standards and make good environment for our visitors. Please leave your comment